Island Pharmaceuticals Ltd (AU:ILA) has released an update.
Island Pharmaceuticals Ltd has initiated the Phase 2a segment of its groundbreaking PROTECT trial, administering an attenuated dengue virus to subjects as part of a study aimed at finding a preventative and therapeutic solution for the globally rampant dengue fever. The trial is distinguished by its dual-phased approach, assessing both prophylactic and therapeutic responses to the virus, with full Phase 2a results expected by year-end and Phase 2b set to start early 2025. The company is also hosting an investor webinar to discuss the trial’s progress and other company developments, including a new antiviral acquisition.
For further insights into AU:ILA stock, check out TipRanks’ Stock Analysis page.